Inspire Medical initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst Kallum Titchmarsh initiated coverage of Inspire Medical with an Overweight rating and $250 price target. With a solid track record of execution, multiple catalysts on the horizon, and an emerging profitability profile, Inspire is well positioned to exceed Street estimates over the mid-term, the analyst tells investors in a research note. The firm says the stock’s valuation looks attractive relative to peers and history. It believes the company has a “considerably more appealing” sales and profitability profile relative to peers.